Why the study?
Does cardiac resynchronization therapy (CRT) result in different rates of major adverse cerebral and cardiovascular events (MACCE) in patients with cardiac sarcoidosis compared to those with dilated cardiomyopathy?
Population
40 patients receiving cardiac resynchronization therapy, including 11 consecutive patients with cardiac…
Comparison
Cardiac resynchronization therapy in patients… vs Cardiac resynchronization therapy in patients…
Design
Cohort
Follow-up
Mean 465 ± 383 days for CS and 729 ± 393 days for DCM
Authors
Loading...
CRT outcomes in cardiac sarcoidosis warrant caution; small retrospective comparison leaves open equivalence to dilated cardiomyopathy.
Does cardiac resynchronization therapy (CRT) result in different rates of major adverse cerebral and cardiovascular events (MACCE) in patients with cardiac sarcoidosis compared to those with dilated cardiomyopathy?
Patients with cardiac sarcoidosis receiving CRT have significantly worse long-term outcomes (higher MACCE rates) compared to those with dilated cardiomyopathy, suggesting caution in its application for this population.
Yufu et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: